Emergency Medicine Cardiac Research and Education Group





CRUSADE
CRUSADE Quality Improvement Initiative

Launched in 2001, CRUSADE is a national quality improvement initiative, designed to increase the practice of evidence-based medicine for patients diagnosed with non-ST segment elevation acute coronary syndromes (NSTE ACS) (i.e., unstable angina or NSTE myocardial infarction).

Through a continuous cycle of data collection, performance feedback and quality improvement interventions, over 500 participating sites in the US are consistently improving the standard of care for patients with NSTE ACS. Because of the dedication of the participating hospitals to this mission, over 200,000 cases have been submitted to the CRUSADE database. For more information visit the CRUSADE website.

In 2007, a milestone occurred. Duke Clinical Research Institute and its CRUSADE leadership joined forces with the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR™) to launch a new initiative to improve the safety and outcomes for patients with ACS through the development of NCDR-ACTION™. This initiative will combine the data collection and quality reporting features of two leading national ACS registries to create the largest and most comprehensive national cardiovascular patient database ever developed. For more information visit the NCDR-ACTION Registry™ visit the website or call 800-257-4737 for more information.







With well over one and a half million combined Emergency Department (ED) visits at EMCREG sites annually, EMCREG-International is ideally positioned to conduct clinical trials quickly and efficiently. Additionally, as academic emergency clinician educators, EMCREG provides an ideal format for educating the emergency medicine community on cutting-edge evidence-based research, and facilitate acceptance and understanding of current treatment guidelines.

The wealth of experience and clinical acumen associated with such a geographically diverse network of veteran clinician researchers has resulted in the development of the consultation arm of EMCREG-International. These consultation efforts are geared toward helping companies understand both the clinical usefulness and obstacles associated with embracing a new diagnostic or treatment technology in the clinical ED setting. The drive to identify and assess new technologies is equally important to the clinicians making up the EMCREG network as it is to the manufacturers of diagnostic and therapeutic modalities.

The ability to consult with such a large number of well known and geographically diverse emergency physicians in a round table discussion setting has proved invaluable to industry efforts to assess the clinical utility of a promising new diagnostic or therapeutic technology. Will a promising technology ultimately be practical in the clinical ED setting in its current form?; What are the practical, clinical and political obstacles to adopting promising new technologies?; and What alterations to a technology or its marketing would allow its utility and acceptance in the ED to be realized? This ability to rapidly organize such an expert panel with minimal effort has proved appealing for companies facing short development timelines.

Please feel free to contact our offices if the idea of a consultation roundtable or collaboration interests your organization.





General navigation: Home | Member roster | Consultation | Our history | Contact
News & Events: Literature news archives | EM and related events
Education: CME monographs | Articles & Print
Publications: Member publications | Monographs

Legal information

EMCREG™ - International
4555 Lake Forest Drive
Suite 650
Cincinnati, Ohio 45242

Fell free to contact us toll-free at 1-866-4EMCREG (436-2734)



Advanced Search

15 May 2008
A recent NEJM article reports that cardiac troponin elevation is associated with increased in-hospital mortality in patients with acute decompensated heart failure
15 May 2008
Research suggestes that the use of multiple biomarkers of renal and cardiovascular abnormalities improves cardiovascular disease risk stratification.
13 May 2008
A study reports that STEMI patients with combined factors such as older age, female gender, Hispanic or Black race, and diabetes have much longer delays in STEMI presentation.
12 May 2008
Bleeding risk cut in half in ACS patients by switching from unfractionated heparin or low molecular weight heparin to bivalirudin.
9 May 2008
Researchers report that the additional patients diagnosed with MI rather than UA since the definition of MI was redefined have an even higher long-term mortality.
9 May 2008
Experts suggest that discrepancies in recommendations for optimal anticoagulation treatment in updated US and European ACS management guidelines are confusing for clinicians.
8 May 2008
Researchers report that "midregional" pro-atrial natriuretic peptide is a strong predictor of adverse outcome after AMI, and gives complementary information when combined with measurement of the prohormone of BNP.
7 May 2008
A study reports effective triage using a portable ultrasound device that can accurately screen emergency department patients with dyspnea for venous thromboembolism.
1 May 2008
Researchers in Israel propose that patients with transient ST-elevation myocardial infarction (TSTEMI) may benefit from immediate, intense medical therapy and an early invasive approach.
28 April 2008
Research suggests that monitoring levels of NT-proBNP is better than clinical assessment at predicting outcome in heart failure outpatients.
25 April 2008
Researchers test a new 15-minute rapid point-of-care D-dimer assay with diagnostic performance comparable to conventional laboratory D-dimer tests.
24 April 2008
The ACUITY data suggests ACS patients with diabetes are likely to have more ischemia and bleeding than other patients, but these adverse events can be minimized by bilvalirudin monotherapy
NEWS ARCHIVES:
©Copyright EMCREG-International™. All rights reserved